Adverse drug reactions in neonates and infants: A population-tailored approach is needed

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 788-795

  Allegaert, Karel ^a,b   Van Den Anker, Johannes N ^c,d,e,f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

adverse drug reaction; developmental pharmacology; infant; newborn; pharmacovigilance

Indexed keywords

ALGORITHM; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PHARMACOLOGY; DRUG FORMULATION; DRUG LABELING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; INFANT DISEASE; MORBIDITY; NEWBORN DISEASE; OFF LABEL DRUG USE; POLYPHARMACY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION; TOXICOLOGY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMAN; INFANT; NEWBORN; RISK FACTOR;

ALGORITHMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INFANT; INFANT, NEWBORN; PHARMACOVIGILANCE; RISK FACTORS;

EID: 84942551307     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12430     Document Type: Article

References (50)

1. World Health Organization. The importance of pharmacovigilance; safety monitoring of medicinal products. Geneva, World Health Organization, 2002. Available at www.who.int/medicinedocs/en/d/Js4893e (last accessed 22 March 2014).
2. Fabiano V, Mameli C, Zuccotti GV,. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. Expert Opin Drug Saf 2012; 11: 95-105.
3. Ligi I, Arnaud F, Jouve E, Tardieu S, Sambuc R, Simeoni U,. Iatrogenic events in admitted neonates: a prospective cohort study. Lancet 2008; 371: 404-410.
4. Sharek PJ, Horbar JD, Mason W, Bisarya H, Thurm CW, Suresh G, Gray JE, Edwards WH, Goldmann D, Classen D,. Adverse events in the neonatal intensive care unit: development, testing, and findings of a NICU-focused trigger tool to identify harm in North American NICUs. Pediatrics 2006; 118: 1332-1340.
5. Aranda JV, Portuguez-Malavasi A, Collinge JM, Germanson T, Outerbrigde EW,. Epidemiology of adverse drug reactions in the newborn. Dev Pharmacol Ther 1982; 5: 173-184.
6. Kugelman A, Inbar-Sanado E, Shinwell ES, Makhoul IR, Leshem M, Zangen S, Wattenberg O, Kaplan T, Riskin A, Bader D,. Iatrogenesis in neonatal intensive care units: observational and interventional, prospective, multicenter study. Pediatrics 2008; 122: 550-555.
7. European Medicines Agency. Medication errors, follow up actions from workshop. Implementation plan 2014-2015, 15 April 2014. Human Medicines Research and development support. London, European Medicines Agency, 2014. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Other/2014/04/WC500165496.pdf (last accessed 20 June 2014).
8. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE,. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167.
9. Allegaert K, Langhendries JP, van den Anker JN,. Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 2013; 172: 429-435.
10. Campbell K,. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust 1951; 14: 48-50.
11. Andersen DH, Blanc WA, Crozier DN, Silverman WA,. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956; 18: 614-625.
12. Sutherland JM,. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. Am J Dis Child 1959; 97: 761-767.
13. Gershanik J, Boeclerr B, Ensley H, McCloskey S, George W,. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982; 307: 1384-1388.
14. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader S, Bader D, Yurman S, Dolfin T, Kogan A, Dolberg S, Arbel E, Goldberg M, Gur I, Naor N, Sirota L, Mogilner S, Zaritsky A, Barak M, Gottfried E,. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-181.
15. Saugstad OD, Aune D,. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 2014; 105: 55-63.
16. Food and Drug Administration. FDA drug safety communication: serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm (last accessed 8 March 2011).
17. FDA. Information for healthcare professionals: ceftriaxone (marketed as Rocephin and generics). 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm (last accessed 24 December 2008).
18. Kemper EM, Merkus M, Wierenga PC, Van Rijn PC, Van der Werff D, Lie-A-Huen L, Offringa M,. Towards evidence-based pharmacotherapy in children. Paediatr Anaesth 2011; 21: 183-189.
19. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA,. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012; 51: 105-117.
20. Krekels EH, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M, Danhof M, Knibbe CA,. Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet 2014; 53: 553-563.
21. Benjamin DK Jr, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS,. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006; 296: 1266-1273.
22. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR,. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117: 1979-1987.
23. Turner MA, Duncan JC, Shah U, Metsvaht T, Varendi H, Nellis G, Lutsar I, Yakkundi S, McElnay JC, Pandya H, Mulla H, Vaconsin P, Storme T, Rieutord A, Nunn AJ,. Risk assessment of neonatal excipient exposure: lessons from food safety and other areas. Adv Drug Deliv Rev 2013 10.1016/j.addr.2013.11.003.
24. Hakkarainen KM, Gyllensten H, Jönsson AK, Andersson Sundell K, Petzold M, Hägg S,. Prevalence, nature and potential preventability of adverse drug events-A population-based medical record study in 4970 adults. Br J Clin Pharmacol 2014 10.1111/bcp.12314.
25. Aagaard L, Christensen A, Holme-Hansen E,. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br J Clin Pharmacol 2010; 70: 481-491.
26. Smyth RM, Gargon E, Kirkham J, Cresswell L, Golder S, Smyth R, Williamson P,. Adverse drug reactions in children-a systematic review. PLoS ONE 2012; 7: e24061.
27. Le J, Nguyen T, Law AV, Hodding J,. Adverse drug reactions among children over a 10 year period. Pediatrics 2006; 118: 555-562.
28. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ,. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110: e53.
29. Castro-Pastrana LI, Carleton BC,. Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. J Popul Ther Clin Pharmacol 2011; 18: e76-e88.
30. Lazou K, Farini M, Koutkias V, Drossou V, Maglaveras N, Bassiliades N,. Adverse drug event prevention in neonatal care: a rule-based approach. Stud Health Technol Inform 2013; 186: 170-174.
31. Ward RM, Kern SE,. Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ther 2009; 86: 585-587.
32. Choonara I,. Educational paper: aspects of clinical pharmacology in children-pharmacovigilance and safety. Eur J Pediatr 2013; 172: 577-580.
33. Rieder M,. New ways to detect adverse drug reactions in pediatrics. Pediatr Clin North Am 2012; 59: 1071-1092.
34. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, Goldmann DA,. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285: 2114-2120.
35. Chedoe I, Molendijk HA, Dittrich TA, Jansman FG, Harting JW, Brouwers JR, Taxis K,. Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety. Drug Saf 2007; 30: 503-513.
36. Morriss FH, Abramowitz PW, Nelson SP, Milavetz G, Michael SL, Gordon SN, Pendergast JF, Cook EF,. Effectiveness of a barcode medication administration system in reducing preventable adverse drug events in a neonatal intensive care unit: a prospective cohort study. J Pediatr 2009; 154: 363-368.
37. Rosenbluth G, Wilson SD,. Pediatric and neonatal patients are particularly vulnerable to epinephrine dosing errors. Ann Emerg Med 2010; 56: 704-705.
38. Aguado-Lorenzo V, Weeks K, Tunstall P, Turnock K, Watts T, Arenas-Lopez S,. Accuracy of the concentration of morphine infusions prepared for patients in a neonatal intensive care unit. Arch Dis Child 2013; 98: 975-979.
39. Allegaert K, Anderson BJ, Vrancken M, Debeer A, Desmet K, Cosaert K, Tibboel D, Devlieger H,. Impact of a paediatric vial on the magnitude of systematic medication errors in preterm neonates: amikacin as an example. Paed Perinatal. Drug Ther 2006; 7: 59-63.
40. Nunn A, Craig JV, Shah UU, Barker C, Craig J, Peak M, Ford J, Turner M,. Estimating the requirement for manipulation of medicines to provide accurate doses for children. Eur J Hosp Pharm 2013; 20: 3-7.
41. Horbar JD, Carpenter JH, Buzas J, Soll RF, Suresh G, Bracken MB, Leviton LC, Plsek PE, Sinclair JC,. Collaborative quality improvement to promote evidence based surfactant for preterm infants: a cluster randomised trial. BMJ 2004; 329: 1004.
42. Cronin CM, Baker GR, Lee SK, Ohlsson A, McMillan DD, Seshia MM, Canadian Neonatal Network EPIQ Study Group. Reflections on knowledge translation in Canadian NICUs using the EPIQ method. Healthc Q 2011; 14: 8-16.
43. Victor S, Dickinson H, Turner MA,. Plasma aminotransferase concentrations in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011; 96: F144-145.
44. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K,. Postnatal trends in creatininemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatr Nephrol 2011; 26: 1843-1849.
45. Kahn MG, Bailey LC, Forrest CB, Padula MA, Hirschfeld S,. Building a common pediatric research terminology for accelerating child health research. Pediatrics 2014; 133: 516-525.
46. Ferrajolo C, Coloma PM, Verhamme KM, Schuemie MJ, de Bie S, Gini R, Herings R, Mazzaglia G, Picelli G, Giaquinto C, Scotti L, Avillach P, Pedersen L, Rossi F, Capuano A, van der Lei J, Trifirõ G, Sturkenboom MC, EU-ADR consortium. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf 2014; 37: 99-108.
47. Du W, Lehr VT, Leih-Lai M, Koo W, Ward RM, Rieder MJ, van den Anker JN, Reeves JH, Mathew M, Lulic-Botica M, Aranda JV,. An algorithm to detect adverse drug reactions in the neonatal intensive care unit: a new approach. J Clin Pharmacol 2012; 53: 87-95.
48. Kelly LE, Chaudry SA, Rieder MJ, 't Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Koren G,. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLoS ONE 2013; 8: e70073.
49. Van den Anker JN,. Is it safe to use opioids for obstetric pain while breastfeeding? J Pediatr 2012; 160: 4-6.
50. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N, Huggins GS, Aranda JV, Davis JM,. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013; 309: 1821-1827.